-transparent.png){kind=logo}
A phase II study of AMSA in previously treated patients with metastatic malignant melanoma was conducted. The dose schedule of AMSA was 40 mg/m2/day for 3 days repeated at 3-week intervals. Among the 30 evaluable patients, one achieved a complete response, one a partial response, and four had minor responses. Side effects included mild nausea and vomiting and moderate degree of myelosuppression. AMSA has poor activity against previously treated metastatic melanoma.
Related Publications
S S Legha, and
S W Hall, and
K C Powell, and
M A Burgess, and
R S Benjamin, and
J U Gutterman, and
G P Bodey
January 1979,
Cancer treatment reports,
S S Legha, and
S W Hall, and
K C Powell, and
M A Burgess, and
R S Benjamin, and
J U Gutterman, and
G P Bodey
January 1980,
Cancer treatment reports,
S S Legha, and
S W Hall, and
K C Powell, and
M A Burgess, and
R S Benjamin, and
J U Gutterman, and
G P Bodey
January 1980,
Cancer treatment reports,
S S Legha, and
S W Hall, and
K C Powell, and
M A Burgess, and
R S Benjamin, and
J U Gutterman, and
G P Bodey
June 1982,
American journal of clinical oncology,
S S Legha, and
S W Hall, and
K C Powell, and
M A Burgess, and
R S Benjamin, and
J U Gutterman, and
G P Bodey
January 1980,
Cancer treatment reports,
S S Legha, and
S W Hall, and
K C Powell, and
M A Burgess, and
R S Benjamin, and
J U Gutterman, and
G P Bodey
February 1982,
Gan to kagaku ryoho. Cancer & chemotherapy,
S S Legha, and
S W Hall, and
K C Powell, and
M A Burgess, and
R S Benjamin, and
J U Gutterman, and
G P Bodey
January 1981,
Cancer clinical trials,
S S Legha, and
S W Hall, and
K C Powell, and
M A Burgess, and
R S Benjamin, and
J U Gutterman, and
G P Bodey
January 1980,
Cancer treatment reports,
S S Legha, and
S W Hall, and
K C Powell, and
M A Burgess, and
R S Benjamin, and
J U Gutterman, and
G P Bodey
August 1983,
American journal of clinical oncology,
S S Legha, and
S W Hall, and
K C Powell, and
M A Burgess, and
R S Benjamin, and
J U Gutterman, and
G P Bodey
January 1980,
Cancer treatment reports,
